ScreenerHero

SRZN Surrozen, Inc.

NAS · US · Healthcare · Biotechnology · surrozen.com
27.97USD+11.23%Mkt Cap: 328.75M $P/E: —

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target variou…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap328.75M USD
Enterprise Value214.22M USD
Revenue (TTM)11.51M USD
Gross Profit-23.07M USD
Net Income (TTM)-242.03M USD
Revenue/Share1.14 USD
Last Price27.97 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.30
PEG—
EV/EBITDA-4.85
EV/Revenue18.61
P/S26.93
P/B-1.42
EPS (TTM)-39.08
EPS (Forward)-4.19
52W Range
11.3963% of range37.83
52W High37.83 USD
52W Low11.39 USD
Profitability
Gross Margin-200.38%
Oper. Margin-207.40%
EBITDA Margin0.00%
Profit Margin-6960.77%
ROE128.90%
ROA-245.15%
Growth
Revenue Growth408.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.24M USD
CapEx (TTM)128.00K USD
FCF Margin-188.96%
FCF Yield-6.62%
Net Debt-95.72M USD
Net Debt/EBITDA2.17
Balance Sheet
Debt/Equity-0.04
Current Ratio12.14
Quick Ratio11.88
Book Value/Sh-18.60 USD
Cash/Share8.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateDec 14, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)48.40 USD
Upside (mean)+73.0%
Target Range40.00 USD – 54.00 USD
40.00+73.0% to mean54.00
# Analysts5
Ownership
Shares Out.11.75M
Float3.74M
Insiders3.14%
Institutions112.39%
Short Interest
Short Ratio12.0d
Short % Float33.64%
Short % Out.18.68%
Shares Short2.20M
Short (prev mo.)1.25M
Technical
SMA 5022.93 (+22.0%)
SMA 20024.58 (+13.8%)
Beta0.47
S&P 52W Chg16.45%
Avg Vol (30d)741.79K
Avg Vol (10d)1.78M
Technical Indicators
RSI (14)55.6
MACD1.6282
MACD Signal1.5104
MACD Hist.+0.1178
BB Upper36.66 USD
BB Middle24.50 USD
BB Lower12.34 USD
BB Width99.25%
ATR (14)2.980 USD
Vol Ratio (20d)0.68x